Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. (a British Virgin Islands company) covers the month of May 2024, with the report dated May 14, 2024. The filing primarily discloses the execution and closing of a new securities purchase agreement and provides updates on prior convertible note transactions with Streeterville Capital, LLC.
Key Financial Metrics and Debt Obligations
The filing details three convertible promissory notes issued to Streeterville Capital, LLC. No revenue, profit, or operating cash flow data is provided in this document.
| Note Date | Principal Amount | Gross Proceeds | Interest Rate | Original Issue Discount (OID) | Transaction Fees |
|---|---|---|---|---|---|
| May 9, 2024 | $797,500.00 | $750,000.00 | 6% p.a. (compounding daily) | $47,500.00 | $20,000.00 |
| March 27, 2024 | $531,666.67 | $500,000.00 | 6% p.a. (compounding daily) | $31,666.67 | $20,000.00 |
| December 13, 2023 | $531,666.67 | $500,000.00 | 6% p.a. (compounding daily) | $31,666.67 | $20,000.00 |
Total Outstanding Principal: $1,860,833.34
Total Gross Proceeds Received: $1,750,000.00
Material Changes and Transaction Terms
The most significant material change is the issuance of the May 2024 Note, which closed on May 13, 2024. Key terms common to all three notes include:
- Conversion: Notes are convertible into ordinary shares ($0.08 par value).
- Maturity: Due 12 months after the respective closing dates.
- Prepayment: Company may prepay at 120% of the outstanding balance.
- Redemption Rights: Investor may redeem notes starting 6 months after closing, subject to monthly caps ($300,000 for May 2024 Note; $200,000 for March and December notes). Redemption can be in cash or shares, but cash is mandatory if "Equity Conditions Failure" occurs.
- Conversion Price: Lower of the initial Lender Conversion Price ($3.00) or 80% of the average lowest VWAP during the 15 trading days preceding the redemption notice.
- Trigger Events: Investor may increase the note balance by 15% (Major Trigger Event) or 5% (Minor Trigger Event) upon occurrence of defined events.
- Default Interest: Interest rate increases to the lesser of 15% per annum or the maximum permitted by law upon an Event of Default.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding operational performance. However, it highlights several financial risks and contingencies:
- Liquidity Risk: The company has significant short-term debt obligations with potential for accelerated repayment or increased principal upon Trigger Events.
- Dilution Risk: Conversion and redemption features allow for significant share issuance at a discount to market price (80% of VWAP), potentially diluting existing shareholders.
- Cash Flow Contingency: The company is required to pay redemption amounts in cash if Equity Conditions Fail, creating a potential liquidity strain.
- Listing Maintenance: The company agreed to maintain its Nasdaq listing while the notes are outstanding.
Investor Verification Checklist
- Verify the company's current cash position to assess ability to meet potential redemption demands or prepayment penalties (120% of balance).
- Review the definitions of "Trigger Events," "Major Trigger Event," and "Minor Trigger Event" in the attached exhibits to understand conditions that could increase debt principal.
- Confirm the current trading volume and VWAP of ordinary shares to estimate potential dilution if notes are converted or redeemed in shares.
- Check for any subsequent filings regarding "Equity Conditions Failure" which would mandate cash redemption.
- Monitor the company's compliance with Nasdaq listing requirements as a covenant of these agreements.